Abbott Laboratories is rated a Buy due to strong growth in its medical devices and diagnostics segments, which now make up 70% of its revenue. The company’s recent acquisition of Exact Sciences has accelerated diagnostics growth. Abbott plans to spin off its Nutrition business, which is expected to increase its growth rate by 0.5-1%, expand gross margin by 2%, and improve operating margin by 1%. Management targets 6% sales growth and 7% EPS growth by 2026, with margin expansion following the spin-off, making the stock attractively valued below historical averages.
Abbott Laboratories trades at USD 104.02 on Pluang as of Oct 26, 2026 19:02 WIB, showing a modest 0.31% increase in one day. The stock holds a significant market cap of $179.44 billion and offers a dividend yield of 2.43%, reflecting steady investor interest. This trading context complements the company's strategic moves in diagnostics and planned spin-off, which aim to enhance growth and margins.
